Off‐therapy durability of response to entecavir therapy in hepatitis B e antigen‐negative chronic hepatitis B patients
Wen‐Juei Jeng, I‐Shyan Sheen, Yi‐Cheng Chen, Chao‐Wei Hsu, Rong‐Nan Chien, Chia‐Ming Chu, Yun‐Fan Liaw – 6 June 2013 – The optimal duration of nucelos(t)ide analog (Nuc) treatment in hepatitis B e antigen (HBeAg)‐negative patients with chronic hepatitis B virus (HBV) infection is unknown. The Asian Pacific Association for the Study of the Liver (APASL) guidelines recommend that treatment can be discontinued if undetectable HBV‐DNA has been documented on three occasions ≥6 months apart.